IL-SHIPPEO
23.4.2024 10:40:26 CEST | Business Wire | Press release
Shippeo, a leading provider of multimodal shipment visibility, announced today their Spring 2024 Platform release, introducing over 70 new features and enhancements, including a new parcel tracking solution rebuilt from the ground up, as well as improvements to road, ocean container, and carbon emissions tracking, along with significant user experience improvements.
“I’m thrilled to announce that our latest Spring platform release is available to customers from today,” says Chief Product Officer, Anand Medepalli. “Our entirely rebuilt parcel tracking solution that we’re releasing today is market-leading. Reengineered from the ground up, Parcel Visibility offers enhanced scalability to support our continued expansion into North America and APAC, where we are seeing significant appetite for a simpler, more convenient tool that delivers the high data quality and reliability that shippers and freight forwarders demand in this rapidly changing and competitive market. In addition, we’re taking the carbon footprint measurement capabilities for users even further with new Carbon Visibility features, while bringing a number of new features and enhancements to our Road and Ocean Visibility solutions.”
All-new parcel tracking solution to boost customer experience
A newly imagined, simple and convenient parcel tracking solution helps shippers and freight forwarders boost customer experience while accelerating invoicing. With more granular visibility into parcel shipment milestones, recipients have greater oversight of where their shipments are, when they will arrive, while offering shippers easier identification of incomplete delivery root causes. Key features include:
- 360 degree event tracking coverage available after booking, for all major parcel carriers and all in one platform
- Tracking links and customer portals provide recipients with detailed parcel journey information, in client’s own branding
- Aggregated delivery timestamps for users, enabling easy sharing, faster invoicing and optimized cash flow
- On-time In-full performance insights to help users assess carrier performance
Advanced, accurate carbon emissions reporting capabilities enabling targeted reductions
Organizations are increasingly required to measure scope 3 carbon emissions, to comply with rapidly evolving regulations, as a result of stakeholder or customer pressure, or simply to measure progress towards reaching carbon neutrality goals. As a result, carbon emissions reporting continues to rise up the priority list for supply chain management, and shippers in general. Shippeo’s latest Spring Release brings new capabilities to the platform’s GLEC framework-accredited Carbon Visibility solution, making calculations more accurate across all transport modes, and offering powerful insights needed to enable targeted emissions reductions.
- Ocean Carrier Intermodal calculations: Ocean container transport carbon calculations now take into account pre and/or post carriage legs when booked end to end with an ocean carrier, simplifying data collection for a more comprehensive picture of environmental impact, while identifying the most carbon-intensive, and potentially most expensive, legs for door-to-door shipments
- Insetting support: Shippers can now override the default fuel type for truck loads and ocean containers, and select from biofuel and electricity fuel types, to account for lower emissions levels achieved through insetting agreements with road or ocean carriers
- Data completeness dashboards: After launching the same feature for Ocean Visibility users last November, Road Visibility users can now also access a scorecard detailing how complete road shipment data is, identifying missing data, such as weight, truck size, fuel type, and more, to help users take steps to improve calculation accuracy
Further features for Road and Ocean Visibility enhancing user experience, predictive ETA performance, and data quality
The platform update will also introduce new features and enhancements to the Road and Ocean Visibility solutions, including:
- All-new Homepage: An entirely new and fully customizable homepage is coming for all users (including carriers), making it possible to drag and drop widgets and configure their own control center, KPIs and visualize all of their most important action items in one place. Metrics for shipments in various stages can be viewed at a glance, for easier identification and management of deliveries at risk
- Long-distance shipment ETA: Shippeo’s accuracy SLA-backed predictive ETA has been enhanced for full truckload shipments where journey times are two or more days, with accuracy increasing by as much as 70%
- Container Journey identification: Enhanced logic improves identification of container journey boundaries, offering greater data quality when operational processes are more complex and data received from ocean carriers via EDI 315 messages is incomplete
New Developer Portal for more autonomous API integrations and monitoring:
A new portal offers developers a suite of tools for faster, more autonomous API integrations and interface monitoring, for both Shipper and Carrier IT teams, including:
- Full autonomy to interface: Access clear API documentation sorted by transport mode and use-case, examples and screenshots to illustrate steps, explanations of technical language used, and detailed swaggers enabling developers to interface with little to no additional support
- Authentication method selection: Users can choose between JWT or Oauth2 authentication methods
- Integration health monitoring: Self-service analytics, alerts and monitoring allow customers to autonomously check logs and dashboards to monitor the health of their API interfaces and debug errors
About Shippeo
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more resilient, sustainable, and customer-centric supply chains. This is made possible with highly accurate real-time operational visibility and Transport Process Automation™ to streamline transportation processes, reduce latency and improve operational efficiency. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Ahold Delhaize, AkzoNobel, Amazon, Avery Dennison, Arlanxeo, Barilla, Birra Peroni, Bosch Siemens Hausgeräte, Carrefour, Coca-Cola HBC, DP World, Evonik, Fujifilm, Jaguar Land Rover, Hartmann Group, Heineken, Kuehne+Nagel, L’Oréal, LVMH, Renault Group, Sabic, Saint-Gobain, XPO Logistics and Yamaha Motor, trust Shippeo to track more than 50 million shipments per year across 130 countries. Learn more at www.shippeo.com, LinkedIn, Facebook, X (formerly Twitter)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423236212/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
